Cyclophosphamide abrogates the expansion of CD4+Foxp3+ regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas.

Ping LiFengyang ChenJingbin ZhengYang YangYuan LiYifei WangXin Chen

Published in: Cancer biology & medicine (2021)

CY abrogated the effect of BLM on the expansion of Tregs. The combination of these 2 chemotherapeutic agents may represent a safer and more effective therapy in the treatment of cancer patients, and thus merits future clinical evaluation.

Keyphrases

regulatory t cells
clinical evaluation
dendritic cells
low dose
stem cells
immune response
current status
mesenchymal stem cells